Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 1,299 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $24.00, for a total value of $31,176.00. Following the transaction, the insider owned 399,989 shares of the company’s stock, valued at $9,599,736. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total transaction of $10,714.00.
- On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
- On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00.
Adaptive Biotechnologies Stock Up 2.4%
Adaptive Biotechnologies stock traded up $0.54 during mid-day trading on Monday, reaching $23.11. The stock had a trading volume of 2,591,170 shares, compared to its average volume of 2,341,132. The company has a 50-day moving average price of $19.43 and a two-hundred day moving average price of $16.65. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of -56.37 and a beta of 2.08. Adaptive Biotechnologies Corporation has a one year low of $10.19 and a one year high of $24.57.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in Adaptive Biotechnologies in the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC increased its stake in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies in the fourth quarter worth approximately $51,000. Finally, Strive Financial Group LLC acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $52,000. 99.17% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on ADPT shares. Guggenheim upped their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. BTIG Research upped their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen lifted their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley lifted their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, JPMorgan Chase & Co. cut their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.33.
Check Out Our Latest Research Report on ADPT
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
